12/4
02:53 pm
halo
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]
Low
Report
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]
12/4
01:42 pm
halo
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]
Low
Report
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]
12/4
01:26 pm
halo
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Low
Report
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
12/4
08:43 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
12/2
03:45 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/28
07:02 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/28
02:23 am
halo
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Medium
Report
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term [Yahoo! Finance]
11/27
09:23 am
halo
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here's Why [Yahoo! Finance]
Medium
Report
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here's Why [Yahoo! Finance]
11/25
09:10 am
halo
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Low
Report
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/25
08:30 am
halo
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
11/20
12:37 am
halo
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects [Yahoo! Finance]
Low
Report
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects [Yahoo! Finance]
11/19
07:43 pm
halo
What Recent Analyst Upgrades and Partnerships Mean for Halozyme's Evolving Story and Valuation [Yahoo! Finance]
Low
Report
What Recent Analyst Upgrades and Partnerships Mean for Halozyme's Evolving Story and Valuation [Yahoo! Finance]
11/19
01:46 pm
halo
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis [Seeking Alpha]
Low
Report
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis [Seeking Alpha]
11/18
01:13 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $56.00. They now have a "neutral" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $56.00. They now have a "neutral" rating on the stock.
11/18
08:50 am
halo
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Low
Report
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
11/18
06:02 am
halo
Merus and Halozyme link on subcutaneous petosemtamab [Yahoo! Finance]
Low
Report
Merus and Halozyme link on subcutaneous petosemtamab [Yahoo! Finance]
11/17
07:00 am
halo
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
Low
Report
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
11/16
01:09 am
halo
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at
Wall Str
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at
Wall Str
11/14
02:38 am
halo
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? [Yahoo! Finance]
Medium
Report
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? [Yahoo! Finance]
11/12
09:53 pm
halo
Victory Munder Mid-Cap Core Growth Fund Q3 2025 Commentary [Seeking Alpha]
Medium
Report
Victory Munder Mid-Cap Core Growth Fund Q3 2025 Commentary [Seeking Alpha]
11/7
08:30 am
halo
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
Low
Report
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
11/6
11:37 pm
halo
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Low
Report
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
11/5
04:05 pm
halo
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Medium
Report
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
11/4
07:01 pm
halo
Halozyme Therapeutics (HALO): Earnings Surge 51.7% Challenges Doubts on Profit Growth Sustainability [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO): Earnings Surge 51.7% Challenges Doubts on Profit Growth Sustainability [Yahoo! Finance]
11/4
08:09 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Citizens Jmp from $91.00 to $92.00. They now have a "market outperform" rating on the stock.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Citizens Jmp from $91.00 to $92.00. They now have a "market outperform" rating on the stock.